keyword
Keywords Severe asthma infection advers...

Severe asthma infection adverse event

https://read.qxmd.com/read/35891317/persistent-health-issues-adverse-events-and-effectiveness-of-vaccines-during-the-second-wave-of-covid-19-a-cohort-study-from-a-tertiary-hospital-in-north-india
#21
JOURNAL ARTICLE
Upinder Kaur, Sapna Bala, Aditi Joshi, Noti Taruni Srija Reddy, Chetan Japur, Mayank Chauhan, Nikitha Pedapanga, Shubham Kumar, Anurup Mukherjee, Vaibhav Mishra, Dolly Talda, Rohit Singh, Rohit Kumar Gupta, Ashish Kumar Yadav, Poonam Jyoti Rana, Jyoti Srivastava, Shobha Bhat K, Anup Singh, Naveen Kumar P G, Manoj Pandey, Kishor Patwardhan, Sangeeta Kansal, Sankha Shubhra Chakrabarti
Background There is paucity of real-world data on COVID-19 vaccine effectiveness from cohort designs. Variable vaccine performance has been observed in test-negative case-control designs. There is also scarce real-world data of health issues in individuals receiving vaccines after prior COVID-19, and of adverse events of significant concern (AESCs) in the vaccinated. Methods : A cohort study was conducted from July 2021 to December 2021 in a tertiary hospital of North India. The primary outcome was vaccine effectiveness against COVID-19 during the second wave in India...
July 20, 2022: Vaccines
https://read.qxmd.com/read/35708893/delafloxacin-a-review-in-community-acquired-pneumonia
#22
REVIEW
Arnold Lee, Yvette N Lamb, Matt Shirley
Delafloxacin (BAXDELA® in the USA; Quofenix® in the EU) is an anionic fluoroquinolone antibacterial that is approved for the treatment of community-acquired pneumonia (CAP) and acute bacterial skin and skin structure infections in adults. Delafloxacin demonstrated in vitro activity against Gram-positive and Gram-negative pathogens, including drug-resistant isolates. In a phase III trial in adults with CAP, delafloxacin was noninferior to moxifloxacin when assessed against FDA- and EMA-defined primary endpoints, with both fluoroquinolones achieving high treatment success rates...
June 2022: Drugs
https://read.qxmd.com/read/34954123/respiratory-infections-and-anti-infective-medication-use-from-phase-3-dupilumab-respiratory-studies
#23
JOURNAL ARTICLE
Bob Geng, Claus Bachert, William W Busse, Philippe Gevaert, Stella E Lee, Michael S Niederman, Zhen Chen, Xin Lu, Faisal A Khokhar, Upender Kapoor, Nami Pandit-Abid, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz, Benjamin Ortiz
BACKGROUND: Patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP) experience recurrent respiratory tract infections. Dupilumab targets type 2 inflammation, a common underlying pathophysiology of both conditions, with proven efficacy. OBJECTIVE: To examine investigator-reported respiratory infection adverse events and anti-infective medication use with dupilumab versus placebo in patients with moderate-to-severe asthma or severe CRSwNP. METHODS: We performed a post hoc analysis of the pivotal phase 3 trials LIBERTY ASTHMA QUEST (NCT02414854) and LIBERTY NP SINUS-52 (NCT02898454) in moderate-to-severe asthma and severe CRSwNP, respectively...
March 2022: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/34807989/macrolides-versus-placebo-for-chronic-asthma
#24
REVIEW
Krishna Undela, Lucy Goldsmith, Kayleigh M Kew, Giovanni Ferrara
BACKGROUND: Asthma is a chronic disease in which inflammation of the airways causes symptomatic wheezing, coughing and difficult breathing. Macrolides are antibiotics with antimicrobial and anti-inflammatory activities that have been explored for the long-term control of asthma symptoms. OBJECTIVES: To assess the effects of macrolides compared with placebo for managing chronic asthma. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register up to March 2021...
November 22, 2021: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/34716281/effect-of-crth2-antagonism-on-the-response-to-experimental-rhinovirus-infection-in-asthma-a-pilot-randomised-controlled-trial
#25
JOURNAL ARTICLE
Hugo Farne, Nicholas Glanville, Nicholas Johnson, Tata Kebadze, Julia Aniscenko, Eteri Regis, Jie Zhu, Maria-Belen Trujillo-Torralbo, Onn Min Kon, Patrick Mallia, A Toby Prevost, Michael R Edwards, Sebastian L Johnston, Aran Singanayagam, David J Jackson
BACKGROUND AND AIMS: The chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) antagonist timapiprant improved lung function and asthma control in a phase 2 study, with evidence suggesting reduced exacerbations. We aimed to assess whether timapiprant attenuated or prevented asthma exacerbations induced by experimental rhinovirus (RV) infection. We furthermore hypothesised that timapiprant would dampen RV-induced type 2 inflammation and consequently improve antiviral immune responses...
October 29, 2021: Thorax
https://read.qxmd.com/read/34688774/climate-change-and-global-issues-in-allergy-and-immunology
#26
REVIEW
Susan E Pacheco, Guillermo Guidos-Fogelbach, Isabella Annesi-Maesano, Ruby Pawankar, Gennaro D' Amato, Patricia Latour-Staffeld, Marylin Urrutia-Pereira, Matthew J Kesic, Michelle L Hernandez
The steady increase in global temperatures, resulting from the combustion of fossil fuels and the accumulation of greenhouse gases (GHGs), continues to destabilize all ecosystems worldwide. Although annual emissions must be halved by 2030 and reach net zero by 2050 to limit some of the most catastrophic impacts associated with a warming planet, the world's efforts to curb GHG emissions fall short of the commitments made in the 2015 Paris Agreement. To this effect, July 2021 was recently declared the hottest month ever recorded in 142 years...
December 2021: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/34664263/anti-interleukin-13-and-anti-interleukin-4-agents-versus-placebo-anti-interleukin-5-or-anti-immunoglobulin-e-agents-for-people-with-asthma
#27
REVIEW
Andrew Gallagher, Michaela Edwards, Parameswaran Nair, Stewart Drew, Aashish Vyas, Rashmi Sharma, Paul A Marsden, Ran Wang, David Jw Evans
BACKGROUND: Targeting the immunoglobulin E pathway and the interleukin-5 pathway with specific monoclonal antibodies directed against the cytokines or their receptors is effective in patients with severe asthma. However, there are patients who have suboptimal responses to these biologics. Since interleukin-4 and interleukin-13, signalling through the interleukin-4 receptor, have multiple effects on the biology of asthma, therapies targeting interleukin-4 and -13 (both individually and combined) have been developed...
October 19, 2021: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/34487870/integrated-safety-and-efficacy-among-patients-receiving-benralizumab-for-up-to-five-years
#28
JOURNAL ARTICLE
Stephanie Korn, Arnaud Bourdin, Geoffrey Chupp, Borja G Cosio, Doug Arbetter, Mihir Shah, Esther Garcia Gil
BACKGROUND: Benralizumab is an IL-5Rα-directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma. OBJECTIVE: To evaluate the long-term safety and tolerability of benralizumab among adults treated for up to 5 years. METHODS: This analysis included adults treated with placebo or subcutaneous benralizumab 30 mg every 4 or 8 weeks in the 48-week SIROCCO, 56-week CALIMA, and 28-week ZONDA pivotal trials, who were subsequently enrolled in the 56-week double-blind BORA extension and continued assigned regimens or initiated benralizumab (if previously on placebo) for 16 to 40 weeks, before entering the open-label MELTEMI extension...
September 3, 2021: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/34462967/safety-considerations-of-systemic-janus-kinase-inhibitors-in-atopic-dermatitis-applications
#29
REVIEW
Po-Hsiung Chang, Sheng-Fen Huang, Po-Sheng Chang, Yu Yu
Janus kinase (JAK) inhibitors are emerging treatments for atopic dermatitis (AD). Due to this novel role as a therapeutic option for patients with AD, we aimed to review current evidence on the pathophysiology and the safety and adverse effects (AEs) of oral JAK inhibitors for the treatment of AD utilizing the key terms atopic dermatitis, JAK inhibitors, and adverse effect or event. Our study indicated that oral JAK inhibitors have a moderate safety profile for use in AD in several reviews and phase II or III clinical trials...
November 2021: Journal of Dermatology
https://read.qxmd.com/read/34302758/safety-and-efficacy-of-itepekimab-in-patients-with-moderate-to-severe-copd-a-genetic-association-study-and-randomised-double-blind-phase-2a-trial
#30
RANDOMIZED CONTROLLED TRIAL
Klaus F Rabe, Bartolome R Celli, Michael E Wechsler, Raolat M Abdulai, Xiaodong Luo, Maarten M Boomsma, Heribert Staudinger, Julie E Horowitz, Aris Baras, Manuel A Ferreira, Marcella K Ruddy, Michael C Nivens, Nikhil Amin, David M Weinreich, George D Yancopoulos, Helene Goulaouic
BACKGROUND: Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic variants in the IL-33 pathway were also associated with COPD. On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy...
November 2021: Lancet Respiratory Medicine
https://read.qxmd.com/read/34189338/the-azithromycin-to-prevent-wheezing-following-severe-rsv-bronchiolitis-ii-clinical-trial-rationale-study-design-methods-and-characteristics-of-study-population
#31
JOURNAL ARTICLE
Mythili Srinivasan, Leonard B Bacharier, Charles W Goss, Yanjiao Zhou, Jonathan Boomer, Sarah Bram, Dana Burgdorf, Carey-Ann Burnham, Timothy Casper, Mario Castro, Andrea Coverstone, Matthew Haslam, Watcharoot Kanchongkittiphon, Cadence Kuklinski, Qinghua Lian, Kenneth Schechtman, Gregory A Storch, Kelly True, Meghan A Wallace, Huiqing Yin-DeClue, Elizabeth Ahrens, Jinli Wang, Avraham Beigelman
Severe respiratory syncytial virus (RSV) bronchiolitis in early life is a significant risk factor for future recurrent wheeze (RW) and asthma. The goal of the Azithromycin to Prevent Wheezing following severe RSV bronchiolitis II (APW-RSV II) clinical trial is to evaluate if azithromycin treatment in infants hospitalized with RSV bronchiolitis reduces the occurrence of RW during the preschool years. The APW-RSV II clinical trial is a double-blind, placebo-controlled, parallel-group, randomized trial, including otherwise healthy participants, ages 30 days-18 months, who are hospitalized due to RSV bronchiolitis...
June 2021: Contemporary Clinical Trials Communications
https://read.qxmd.com/read/33977284/targeting-the-biology-of-ageing-with-mtor-inhibitors-to-improve-immune-function-in-older-adults-phase-2b-and-phase-3-randomised-trials
#32
JOURNAL ARTICLE
Joan B Mannick, Grace Teo, Patti Bernardo, Dean Quinn, Kerry Russell, Lloyd Klickstein, William Marshall, Sarb Shergill
BACKGROUND: The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults, including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin (mTOR) inhibitor, was observed to increase IFN-induced antiviral gene expression and decrease the incidence of respiratory tract infections (RTIs) in older adults. Therefore, we aimed to investigate whether oral RTB101 upregulated IFN-induced antiviral responses and decreased the incidence of viral RTIs when given once daily for 16 weeks during winter cold and flu season...
May 2021: The Lancet. Healthy longevity
https://read.qxmd.com/read/33971168/the-inflammatory-profile-of-exacerbations-in-patients-with-severe-refractory-eosinophilic-asthma-receiving-mepolizumab-the-mex-study-a-prospective-observational-study
#33
MULTICENTER STUDY
P Jane McDowell, Sarah Diver, Freda Yang, Catherine Borg, John Busby, Vanessa Brown, Rahul Shrimanker, Ciara Cox, Christopher E Brightling, Rekha Chaudhuri, Ian D Pavord, Liam G Heaney
BACKGROUND: Clinical trials with mepolizumab, a humanised monoclonal antibody against interleukin-5, show a 50% reduction in severe asthma exacerbations in people with severe eosinophilic asthma. Exacerbations in patients treated with mepolizumab seem to be different to exacerbations in those given placebo, as patients treated with mepolizumab report fewer symptoms, have a lower sputum eosinophil count, and smaller fall in peak expiratory flow. We aimed to investigate the inflammatory phenotype and physiological characteristics of exacerbation events in patients with severe eosinophilic asthma who were treated with mepolizumab...
October 2021: Lancet Respiratory Medicine
https://read.qxmd.com/read/33947070/oral-and-topical-vitamin-d-sunshine-and-uvb-phototherapy-safely-control-psoriasis-in-patients-with-normal-pretreatment-serum-25-hydroxyvitamin-d-concentrations-a-literature-review-and-discussion-of-health-implications
#34
REVIEW
Patrick J McCullough, William P McCullough, Douglas Lehrer, Jeffrey B Travers, Steven J Repas
Vitamin D, sunshine and UVB phototherapy were first reported in the early 1900s to control psoriasis, cure rickets and cure tuberculosis (TB). Vitamin D also controlled asthma and rheumatoid arthritis with intakes ranging from 60,000 to 600,000 International Units (IU)/day. In the 1980s, interest in treating psoriasis with vitamin D rekindled. Since 1985 four different oral forms of vitamin D (D2 , D3 , 1-hydroxyvitaminD3 (1(OH)D3 ) and 1,25-dihydroxyvitaminD3 (calcitriol)) and several topical formulations have been reported safe and effective treatments for psoriasis-as has UVB phototherapy and sunshine...
April 29, 2021: Nutrients
https://read.qxmd.com/read/33522964/long-term-outcomes-of-0-1-tacrolimus-eye-drops-in-eyes-with-severe-allergic-conjunctival-diseases
#35
JOURNAL ARTICLE
Hiroyuki Yazu, Kazumi Fukagawa, Eisuke Shimizu, Yasunori Sato, Hiroshi Fujishima
BACKGROUND: Because atopic dermatitis does not heal completely, associated severe atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) often require long-term treatment. This study aims to evaluate the long-term outcomes of using 0.1% tacrolimus eye drops to treat these severe allergic conjunctival diseases. METHODS: Two-hundred-and-seventy eyes of 135 patients diagnosed with AKC or VKC from April 2004 to April 2014 were screened retrospectively...
February 1, 2021: Allergy, Asthma, and Clinical Immunology
https://read.qxmd.com/read/33513152/maternal-prenatal-stress-exposure-and-sex-specific-risk-of-severe-infection-in-offspring
#36
JOURNAL ARTICLE
Monique Robinson, Kim W Carter, Craig E Pennell, Peter Jacoby, Hannah C Moore, Stephen R Zubrick, David Burgner
BACKGROUND: Maternal stressful life events during pregnancy have been associated with immune dysregulation and increased risk for asthma and atopy in offspring. Few studies have investigated whether prenatal stress is associated with increased overall or specific infectious diseases in childhood, nor explored sex differences. We sought to examine the relationship between the nature and timing of maternal stress in pregnancy and hospitalisation with infection in offspring. METHODS: Between 1989 and 1992, exposure data on stressful life events were collected from pregnant women (Gen1) in the Raine Study at 18 and 34 weeks' gestation and linked to statutory state-wide hospital morbidity data...
2021: PloS One
https://read.qxmd.com/read/33406022/upper-respiratory-tract-infection-associated-acute-cough-and-the-urge-to-cough-new-insights-for-clinical-practice
#37
REVIEW
Vitalia Murgia, Sara Manti, Amelia Licari, Maria De Filippo, Giorgio Ciprandi, Gian Luigi Marseglia
Upper respiratory tract infection (URTI)-associated acute cough is the most common symptom both in children and adults worldwide and causes economic and social problems with significant implications for the patient, the patient's family, and the health care system. New pathogenic mechanisms in acute cough, including the urge to cough (UTC) mechanisms, have been recently identified. The brainstem neural network, pharyngeal sensory innervation, airway mechanical stimulation, inflammatory mediators, and postnasal drip actively participate in the onset and maintenance of acute cough and the urge to cough phenomenon...
March 2020: Pediatric Allergy, Immunology, and Pulmonology
https://read.qxmd.com/read/33225983/oral-corticosteroids-for-post-infectious-cough-in-adults-study-protocol-for-a-double-blind-randomized-placebo-controlled-trial-in-swiss-family-practices-ospic-trial
#38
JOURNAL ARTICLE
Christoph Merlo, Stefan Essig, D Oana Brancati-Badarau, Jörg Daniel Leuppi, Benjamin Speich, Tobias E Erlanger, Lars G Hemkens, Andreas Zeller
BACKGROUND: Cough is a common reason for patients to visit general practices. So-called post-infectious cough is defined as lasting 3 to 8 weeks after an upper respiratory tract infection. It can be disabling in daily activities, with substantial impact on physical and psychosocial health, leading to impaired quality of life and increased health care costs. Recommendations for the management of post-infectious cough in primary care are scarce and incoherent. A systematic review and meta-analysis of randomized clinical trials (RCT) assessing patient-relevant benefits and potential harms of available treatments identified six eligible RCTs assessing different treatment regimens (i...
November 23, 2020: Trials
https://read.qxmd.com/read/33125495/comparison-of-acetaminophen-paracetamol-with-ibuprofen-for-treatment-of-fever-or-pain-in-children-younger-than-2-years-a-systematic-review-and-meta-analysis
#39
JOURNAL ARTICLE
Eunicia Tan, Irene Braithwaite, Christopher J D McKinlay, Stuart R Dalziel
IMPORTANCE: Acetaminophen (paracetamol) and ibuprofen are the most widely prescribed and available over-the-counter medications for management of fever and pain in children. Despite the common use of these medications, treatment recommendations for young children remain divergent. OBJECTIVE: To compare acetaminophen with ibuprofen for the short-term treatment of fever or pain in children younger than 2 years. DATA SOURCES: Systematic search of the databases MEDLINE, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials and the trial registers ClinicalTrials...
October 1, 2020: JAMA Network Open
https://read.qxmd.com/read/33061689/psychological-state-and-associated-factors-during-the-2019-coronavirus-disease-covid-19-pandemic-among-filipinos-with-rheumatoid-arthritis-or-systemic-lupus-erythematosus
#40
JOURNAL ARTICLE
Cherica A Tee, Evelyn O Salido, Patrick Wincy C Reyes, Roger C Ho, Michael L Tee
Background: Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are perceived to be more vulnerable to worse COVID-19 infection outcome. Furthermore, severe shortage in hydroxychloroquine supply was experienced. Objective: We presented the psychological responses of Filipino SLE and RA patients to the COVID-19 pandemic and shortage of hydroxychloroquine supply. Methods: A total of 512 completed online surveys from SLE and RA patients were gathered from May 19 to 26, 2020...
2020: Open Access Rheumatology: Research and Reviews
keyword
keyword
64009
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.